16:11 EDT Tandem Diabetes (TNDM) sees FY25 revenue $997M-$1.007B, consensus $999M
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- TNDM Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Tandem Diabetes price target lowered to $45 from $55 at RBC Capital
- Hold Rating for Tandem Diabetes Care Amid Competitive and Macroeconomic Challenges
- Tandem Diabetes initiated with a Neutral at Mizuho
- Tandem announces publication of results from trial of Control-IQ+ AID technology
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue